Update shared on25 Aug 2025
Despite a notable increase in consensus revenue growth forecasts for Calumet, a decline in net profit margin offset the improvement, resulting in an unchanged analyst price target of $19.05.
What's in the News
- Calumet added to multiple Russell indices, including the Russell 2000, 2500, and 3000, as well as corresponding Growth and Value subsets.
- The company is now included in a range of small-cap and completeness benchmarks, expanding its visibility to a broader investor base.
- Index additions span both growth and value styles, highlighting recognition of Calumet’s diverse investment attributes.
- Enhanced index representation may increase demand from passive and quantitative investment funds.
- Broader index inclusion could lead to greater liquidity and improved stock price discovery.
Valuation Changes
Summary of Valuation Changes for Calumet
- The Consensus Analyst Price Target remained effectively unchanged, at $19.05.
- The Consensus Revenue Growth forecasts for Calumet has significantly risen from 5.4% per annum to 8.0% per annum.
- The Net Profit Margin for Calumet has fallen from 0.85% to 0.79%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.